Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis

Clinical Infectious Diseases

Volumn 47, Issue 9, 2008, Pages 1150-1158

  Talan, David A ^a,c   Krishnadasan, Anusha ^a   Abrahamian, Fredrick M ^a   Stamm, Walter E ^b   Moran, Gregory J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; CLINICAL FEATURE; EMERGENCY WARD; ENTEROBACTER INFECTION; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PREVALENCE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PYELONEPHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; STAPHYLOCOCCUS AUREUS; URINALYSIS; UROPATHOGENIC ESCHERICHIA COLI;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CIPROFLOXACIN; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; EMERGENCIES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MIDDLE AGED; OFLOXACIN; PYELONEPHRITIS; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES;

EID: 53349095369     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592250     Document Type: Article

References (34)

1. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing uncomplicated cystitis in women. JAMA 1999; 281:736-8.
2. Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003; 36:183-7.
3. Karlowski JA, Kelly LJ, Thornesberry C, et al. Susceptibility to fluoroquinolones among commonly isolated gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int J Antimicrob Agents 2002; 19:21-31.
4. Karlowski JA, Kelly LJ, Thornesberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46:2540-5.
5. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother 2003; 51:69-76.
6. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006; 27:468-75.
7. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology if resistance across organisms. Clin Infect Dis 2004; 38:655-62.
8. Alós J-I, Serrano M-G, Gómez-Garcés J-L, Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect 2005; 11:199-203.
9. Aguiar JM, Chacon J, Canton R, Baquero F. The emergence of highly fluoroquinolone-resistant E. coli in community-acquired urinary tract infections. J Antimicrob Chemother 1992; 29:349-50.
10. Goettsch W, van Pelt W, Nagelkerke N, et al. Increasing resistance to fluoroquinolones in E. coli from urinary tract infections in The Netherlands. J Antimicrob Chemother 2000; 46:223-8.
11. Kahan NR, Chinitz DP, Waitman DA, Dushnitsky D, Kahan E, Shapiro M. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option? Ann Pharmacother 2006; 40:2223-7.
12. Arslan H, Azap ÖK, Ergönül Ö, Timurkaynak F; Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated for community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56:914-8.
13. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43:2736-41.
14. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim/sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000; 283:1583-90.
15. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford Guide to antimicrobial therapy. 37th ed. Sperryville, VA: Antimicrobial Therapy, 2007.
16. Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999; 14:606-9.
17. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002; 34:1061-6.
18. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother 2001; 47:781-7.
19. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Factors associated with trimethoprim-resistant bacteria isolated from urine samples. J Antimicrob Chemother 1999; 43:841-3.
20. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39:75-80.
21. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001; 135:41-50.
22. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis 2001; 33:615-21.
23. Talan DA, Moran GJ, Mower W, et al.; EMERGEncy ID NET Study Group. EMERGEncy ID NET: an emergency department-based emerging infections sentinel network. Ann Emerg Med 1998; 32:703-11.
24. CLSI. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI document M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
25. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34:1165-9.
26. Burman WJ, Breese PE, Murray BE, et al. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary E. coli isolates. Am J Med 2003; 115:358-64.
27. Colgan R, Johnson JR, Kuskowski M, Gupta K. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated pyelonephritis. Antimicrob Agents Chemother 2008; 52:846-51.
28. Smith SP, Manges AR, Riley L. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by E. coli clonal group composition. Clin Infect Dis 2008; 46:689-95.
29. Johnson JR, Murray AC, Kuskowski MA, et al. Distribution and characteristics of Escherichia coli clonal group A. Emerg Infect Dis 2005; 11:141-5.
30. Johnson JR, Magnes AR, O'Bryan TT, Riley LW. A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet 2002; 359:2249-51.
31. Sandberg T, Englund G, Lincoln K, Nilsson LG. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis 1990; 9:317-23.
32. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs. ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005; 293:949-55.
33. Bailey RR, Peddie BA, Swainson CP. Comparison of netilmicin with cefoperazone for the treatment of severe or complicated urinary tract infections. Aust N Z J Med 1985; 15:22-6.
34. Bailey RR, Begg EJ, Smith AH, et al. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Clin Nephrol 1996; 46:183-6.